Dapagliflozin Clinical Trial Results Indicate Improvement In Key Glycemic Measures In Treatment-Naive Type 2 Diabetes Patients

Findings published on March 27, 2009 in Diabetes Care from a 12-week, Phase IIb dose-ranging study showed that dapagliflozin, a novel, selective, sodium glucose co-transporter2 (SGLT2) inhibitor, produced clinically meaningful reductions across all key glycemic measures studied [glycosylated hemoglobin level (HbA1c), fasting plasma glucose (FPG), and postprandial plasma glucose (PPG)] in treatment-naive type 2 diabetes patients, compared to placebo. The study findings also showed that patients receiving dapagliflozin experienced greater reductions in body weight compared to patients on placebo. Adverse events across dapagliflozin and metformin doses were reported at a similar rate, which...

Want to see the full article?

• Purchase this article for only $3.00